Published in Medical Letter on the CDC and FDA, June 10th, 2007
Following recent successful discussions with the Food and Drug Administration ("FDA"), Protherics has agreed to provide additional manufacturing and stability data requirements to support a Biologicals License Application ("BLA") for Voraxaze(tm) in the US. The FDA has also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA